ReviewMarine drugs2015
Anti-obesity activity of the marine carotenoid fucoxanthin.
Review in Marine drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 2 syntheses or guidelines pooled it, 312 citations in OpenAlex.
- Effects of carotenoid supplementation on glycemic control: a systematic review and meta-analysis of randomized clinical trials.European journal of clinical nutrition · 2025Pooled it
- Pooled it
- Efficacy and Safety of CKDB-322, a Combination ofNutrients · 2026Trial
- Fucoidan and Fucoxanthin Attenuate Hepatic Steatosis and Inflammation of NAFLD through Modulation of Leptin/Adiponectin Axis.Marine drugs · 2021Trial
- Effect of a novel functional tomato sauce (OsteoCol) from vine-ripened tomatoes on serum lipids in individuals with common hypercholesterolemia: tomato sauce and hypercholesterolemia.Journal of translational medicine · 2021Trial
- Double-blind randomised controlled trial of the independent and synergistic effect ofBMJ open · 2017Trial
- A Simple Method for Isolating Fucoxanthin, Which Shows a Wide Range of Physiological Effects, from Microalga,Molecules (Basel, Switzerland) · 2026Article
- Marine-Derived Padina Minor Extract Improves Lipid and Glucose Metabolism in Obese Rats: Evidence for PPARγ and ADIPOR1 Modulation.Nutrients · 2026Article
- Combined Role of Spirulina and Exercise-Based Interventions in Individuals with Overweight and Obesity: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Bioactive Phytoconstituents Targeting Energy Expenditure and Appetite to Combat Obesity: A Comprehensive Review.Current nutrition reports · 2026Review
- Mechanisms behind the anti-diabetic and anti-obesity effects of seaweeds or macroalgae and their bioactive compounds.World journal of diabetes · 2025Review
- Structure Meets Function: Dissecting Fucoxanthin's Bioactive Architecture.Marine drugs · 2025Review
- Commercial importance of seaweeds: an overview.Bioresources and bioprocessing · 2025Review
- Emerging Nanonutraceuticals against Obesity.Small science · 2025Review
- Synergistic Anti-Obesity Effects ofInternational journal of molecular sciences · 2025Article
- Neoxanthin: A Promising Medicinal and Nutritional Carotenoid.Marine drugs · 2025Review
- Fucoxanthin-Loaded Solid Lipid Nanoparticles Exert Potent Therapeutic Efficacy in Combating High-Fat Diet Induced Obesity in Mice.International journal of molecular sciences · 2025Article
- Application of Digester Effluent from Methane Fermentation to the Cultivation of the Haptophyte Tisochrysis lutea Promotes the Accumulation of Photosynthetic Pigments.Marine biotechnology (New York, N.Y.) · 2025Article
- RNA Editing Analysis Reveals Methyl Jasmonic Acid Regulation of Fucoxanthin and Fatty Acid Metabolism inMarine drugs · 2025Article
- Type 2 diabetes remission: multidimensional pharmacological strategies and future perspectives.Frontiers in endocrinology · 2025Review
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nowadays the global tendency towards physical activity reduction and an augmented dietary intake of fats, sugars and calories is leading to a growing propagation of overweight, obesity and lifestyle-related diseases, such diabetes, hypertension, dyslipidemia and metabolic syndrome. In particular, obesity, characterized as a state of low-level inflammation, is a powerful determinant both in the development of insulin resistance and in the progression to type 2 diabetes. A few molecular targets offer hope for anti-obesity therapeutics. One of the keys to success could be the induction of uncoupling protein 1 (UCP1) in abdominal white adipose tissue (WAT) and the regulation of cytokine secretions from both abdominal adipose cells and macrophage cells infiltrated into adipose tissue. Anti-obesity effects of fucoxanthin, a characteristic carotenoid, exactly belonging to xanthophylls, have been reported. Nutrigenomic studies reveal that fucoxanthin induces UCP1 in abdominal WAT mitochondria, leading to the oxidation of fatty acids and heat production in WAT. Fucoxanthin improves insulin resistance and decreases blood glucose levels through the regulation of cytokine secretions from WAT. The key structure of anti-obesity effect is suggested to be the carotenoid end of the polyene chromophore, which contains an allenic bond and two hydroxyl groups. Fucoxanthin, which can be isolated from edible brown seaweeds, recently displayed its many physiological functions and biological properties. We reviewed recent studies and this article aims to explain essential background of fucoxanthin, focusing on its promising potential anti-obesity effects. In this respect, fucoxanthin can be developed into promising marine drugs and nutritional products, in order to become a helpful functional food.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.